DongKook Pharmaceutical Co. Ltd (086450) — Cash Flow-to-Debt Ratio
DongKook Pharmaceutical Co. Ltd (086450) has a Cash Flow-to-Debt Ratio of 0.08x as of December 2025, meaning its operating cash flow of ₩23.53 Billion could theoretically repay 0% of its total liabilities (₩299.16 Billion) in one year. See free cash flow generation of DongKook Pharmaceutical Co. Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
DongKook Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for DongKook Pharmaceutical Co. Ltd across 13 annual periods. Also explore net asset growth rate of DongKook Pharmaceutical Co. Ltd to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for DongKook Pharmaceutical Co. Ltd (2013–2025)
Year-by-year debt coverage analysis for DongKook Pharmaceutical Co. Ltd. For market capitalisation and broader financial context, see DongKook Pharmaceutical Co. Ltd (086450) total market value.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | ₩68.76 Billion | ₩299.16 Billion | ▼ -17.2% |
| 2024 | 0.28x | ₩76.09 Billion | ₩274.19 Billion | ▲ +74.9% |
| 2023 | 0.16x | ₩41.79 Billion | ₩263.36 Billion | ▲ +3.3% |
| 2022 | 0.15x | ₩40.91 Billion | ₩266.39 Billion | ▲ +1.6% |
| 2021 | 0.15x | ₩44.65 Billion | ₩295.51 Billion | ▼ -35.6% |
| 2020 | 0.23x | ₩59.11 Billion | ₩251.80 Billion | ▼ -38.7% |
| 2019 | 0.38x | ₩69.48 Billion | ₩181.51 Billion | ▲ +92.8% |
| 2018 | 0.20x | ₩33.21 Billion | ₩167.22 Billion | ▼ -24.2% |
| 2017 | 0.26x | ₩28.66 Billion | ₩109.37 Billion | ▼ -41.6% |
| 2016 | 0.45x | ₩39.41 Billion | ₩87.78 Billion | ▲ +24.4% |
| 2015 | 0.36x | ₩27.14 Billion | ₩75.18 Billion | ▲ +7.3% |
| 2014 | 0.34x | ₩22.74 Billion | ₩67.60 Billion | ▼ -5.1% |
| 2013 | 0.35x | ₩19.86 Billion | ₩56.02 Billion | — |